旨在描述接受微创降低风险输卵管卵巢切除术的 BRCA 突变患者的卵巢组织超出可见范围和国家综合癌症网络推荐的切缘范围。一项针对接受微创降低风险双侧输卵管卵巢切除术的 BRCA 突变患者的前瞻性研究实施。患者入组发生在 2021 年 10 月至 2023 年之间。根据切片和广泛检查流苏末端方案对组织标本进行分析。前瞻性入组了 20 名患有 BRCA 突变的女性。所有患者均接受微创手术，其中 70% 接受同步子宫切除术 (n = 14)。大约一半的手术是在机器人协助下完成的（n = 9，45%）。一名患者过夜入院（5%）；其他 19 名患者（95%）在手术当天出院。一名患者出现严重并发症并需要重新入院（5%）。对 6 个标本（30%）进行病理检查，发现卵巢组织延伸至可见卵巢之外。在一名患者的左侧（17%）、三名患者的右侧（50%）以及两名双侧延伸（33%）的患者中观察到这种情况。显微镜下卵巢基质超出可见卵巢的距离在 2 至 14 毫米之间，中位数为 5 毫米。在卵巢组织显微扩张的患者中，大多数（n = 5，83%）患有 BRCA2 突变。在接受降低风险微创手术的 BRCA 突变女性中，大约三分之一的卵巢间质显微扩张超出可见卵巢。目前的指南建议切除可见卵巢之外至少 20 毫米的组织，这对于该人群来说可能就足够了。版权所有 © 2024 Elsevier Inc. 保留所有权利。

To describe extension of ovarian tissue beyond visible and National Comprehensive Cancer Network recommended margins among patients with BRCA mutations undergoing minimally invasive risk-reducing salpingo-oophorectomy.A prospective study of patients with BRCA mutations who underwent minimally invasive risk-reducing bilateral salpingo-oophorectomy was conducted. Patient enrollment occurred between October 2021 and 2023. Tissue specimens were analyzed according to the Sectioning and Extensively Examining the Fimbriated End protocol.Twenty women with BRCA mutations were prospectively enrolled. All patients underwent minimally invasive surgery with 70% undergoing concurrent hysterectomy (n = 14). Approximately half of these procedures were performed with robotic assistance (n = 9, 45%). One patient was admitted overnight (5%); the other nineteen were discharged on the day of surgery (95%). One patient experienced a major complication and required readmission (5%). Extension of ovarian tissue beyond the visible ovary was noted on pathologic examination of six specimens (30%). In one patient this was observed on the left (17%), in three on the right (50%), and in two bilateral extension (33%) was noted. The distance ovarian stroma extended microscopically beyond the visible ovary was between 2 and 14 mm, with a median of 5 mm. Among patients with microscopic extension of ovarian tissue, the majority (n = 5, 83%) had a BRCA2 mutation.In women with BRCA mutations undergoing risk-reducing minimally invasive surgery, approximately one third had microscopic extension of ovarian stroma beyond the visible ovary. Current guidelines which recommend resection of at least 20 mm of tissue beyond the visible ovary are likely adequate in this population.Copyright © 2024 Elsevier Inc. All rights reserved.